# GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

Study · id `cardio:ct-nct05356104` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05356104](<https://clinicaltrials.gov/study/NCT05356104>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05356104

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 110 participants.

## Technical summary

Registry record NCT05356104. Randomized; single masking; primary purpose treatment. Start 2022-05-25 (actual); primary completion 2027-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 110 participants (planned count; ClinicalTrials.gov record NCT05356104, source copy `cardio:ctgov-nct05356104-2026-06-05`, retrieved 2026-11-18)
- Started: 2022-05-25 (actual) (ClinicalTrials.gov record NCT05356104, source copy `cardio:ctgov-nct05356104-2026-06-05`, retrieved 2026-11-18)
- Primary completion: 2027-05 (anticipated) (ClinicalTrials.gov record NCT05356104, source copy `cardio:ctgov-nct05356104-2026-06-05`, retrieved 2026-11-18)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT05356104, source copy `cardio:ctgov-nct05356104-2026-06-05`, retrieved 2026-11-18)
- Countries: China; Hong Kong SAR China (ClinicalTrials.gov record NCT05356104, source copy `cardio:ctgov-nct05356104-2026-06-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05356104-2026-06-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
- Acronym: GAPP-SVD
- Condition: Cerebral Small Vessel Disease
- Intervention (Drug): GLP-1 receptor agonist
- Lead sponsor: Chinese University of Hong Kong
- Lead sponsor class: OTHER
- Collaborator: First Affiliated Hospital of Wenzhou Medical University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Cerebral small vessel disease (`cardio:cerebral-small-vessel-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Chinese University of Hong Kong (`cardio:org-chinese-university-of-hong-kong`)
- Registry lists this organization as a collaborator: First Affiliated Hospital of Wenzhou Medical University (`cardio:org-first-affiliated-hospital-of-wenzhou-medical-university`)

## Provenance

Content hash: 573eb6e3a144878646d8841fa6a288a1d8030b13b4166e5732b82f07794f88b2
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
